Table 1.
Comparison of ALT and ATRX/DAXX expression status with clinicopathologic factors of PanNETs
| Clinicopathologic factors | ALT status | ATRX or DAXX expression | ||||||
|---|---|---|---|---|---|---|---|---|
| Number | Negative | Positive | P-value | Intact | Loss | P-value | ||
| Age (years) | ≤60 | 189 | 152 (80.4%) | 37 (19.6%) | 0.441 | 152 (82.2%) | 33 (17.8%) | 0.351 |
| >60 | 80 | 61 (76.2%) | 19 (23.8%) | 61 (77.2%) | 18 (22.8%) | |||
| Sex | Male | 127 | 94 (74.0%) | 33 (26.0%) | 0.048* | 97 (77.6%) | 28 (22.4%) | 0.229 |
| Female | 142 | 119 (83.8%) | 23 (16.2%) | 116 (83.5%) | 23 (16.5%) | |||
| Grade | Grade 1 | 181 | 158 (87.3%) | 23 (12.7%) | <0.001* | 157 (88.7%) | 20 (11.3%) | <0.001* |
| Grade 2 | 80 | 49 (61.2%) | 31 (38.8%) | 50 (63.3%) | 29 (36.7%) | |||
| Grade 3 | 8 | 6 (75.0%) | 2 (25.0%) | 6 (75.0%) | 2 (25.0%) | |||
| Ki-67 index | <3% | 195 | 167 (85.6%) | 28 (14.4%) | <0.001* | 166 (86.9%) | 25 (13.1%) | <0.001* |
| 3–20% | 66 | 40 (60.6%) | 26 (39.4%) | 41 (63.1%) | 24 (36.9%) | |||
| >20% | 8 | 6 (75.0%) | 2 (25.0%) | 6 (75.0%) | 2 (25.0%) | |||
| Size | ≤2 cm | 119 | 112 (94.1%) | 7 (5.9%) | <0.001* | 114 (96.6%) | 4 (3.4%) | <0.001* |
| >2 cm | 150 | 101 (67.3%) | 49 (32.7%) | 101 (68.2%) | 47 (31.8%) | |||
| pT classification | pT1 | 113 | 109 (96.5%) | 4 (3.5%) | <0.001* | 108 (98.2%) | 2 (1.8%) | <0.001* |
| pT2–pT4 | 156 | 104 (66.7%) | 52 (33.3%) | 105 (68.2%) | 49 (31.8%) | |||
| Lymphovascular invasion | Absence | 199 | 173 (86.9%) | 26 (13.1%) | <0.001* | 173 (88.7%) | 22 (11.3%) | <0.001* |
| Presence | 70 | 40 (57.1%) | 30 (42.9%) | 40 (58.0%) | 29 (42.0%) | |||
| Perineural invasion | Absence | 234 | 193 (82.5%) | 41 (17.5%) | 0.001* | 191 (83.4%) | 38 (16.6%) | 0.004* |
| Presence | 35 | 20 (57.1%) | 15 (42.9%) | 22 (62.9%) | 13 (37.1%) | |||
| Lymph node metastasis | Absence | 234 | 194 (82.9%) | 40 (17.1%) | <0.001* | 193 (84.3%) | 36 (15.7%) | <0.001* |
| Presence | 35 | 19 (54.3%) | 16 (45.7%) | 20 (57.1%) | 15 (42.9%) | |||
| Distant metastasis | Absence | 259 | 209 (80.7%) | 50 (19.3%) | 0.002* | 209 (82.3%) | 45 (17.7%) | 0.001* |
| Presence | 10 | 4 (40.0%) | 6 (60.0%) | 4 (40.0%) | 6 (60.0%) | |||
| Insulin expression | Absence | 124 | 86 (69.4%) | 38 (30.6%) | <0.001* | 82 (68.3%) | 38 (31.7%) | <0.001* |
| Presence | 43 | 43 (100.0%) | 0 (0.0%) | 42 (100.0%) | 0 (0.0%) | |||
| GLP-1 expression | Absence | 141 | 105 (74.5%) | 36 (25.5%) | 0.046* | 100 (73.5%) | 36 (26.5%) | 0.038* |
| Presence | 26 | 24 (92.3%) | 2 (7.7%) | 24 (92.3%) | 2 (7.7%) | |||
| Hormone expression | Absence | 94 | 59 (62.8%) | 35 (37.2%) | <0.001* | 55 (61.1%) | 35 (38.9%) | <0.001* |
| Presence | 73 | 70 (95.9%) | 3 (4.1%) | 69 (95.8%) | 3 (4.2%) | |||
*
Statistically significant at P<0.05.